Drug Trial Radar · NCT05255822
INNA-051 Influenza Challenge Study
Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Feb 28, 2022
Primary completion
Aug 23, 2022
Study completion Aug 23, 2022
Sponsor
- Lead sponsor
- ENA Respiratory Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.
Conditions
- Influenza Prophylaxis
Interventions
INNA-051Drug
Liquid for intra-nasal administration
PlaceboOther
Liquid for intra-nasal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the antiviral effect of INNA-051 compared to placebo against influenza virusTime frame: To Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
hVIVO
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.